Xconomy National

Archives

by in

Entry	Author	Date	Location
EnVivo, Biogen, Momenta, & Other Boston-Area Life Sciences Newsmakers	Erin Kutz	12/09/11	Boston
EnVivo Posts Positive Trial of Schizophrenia Drug	Arlene Weintraub	12/05/11	Boston
Third Rock Launches Sage Therapeutics with $35M Series A and Plan to Tackle Brain Diseases	Arlene Weintraub	10/18/11	Boston
Stealthy Karuna Licenses Schizophrenia Drugs from Vanderbilt	Arlene Weintraub	09/28/11	Boston
EnVivo, Backed by Fidelity Biosciences, Tests New Weapon Against Alzheimer’s	Arlene Weintraub	07/25/11	Boston
Zogenix Strategy Unfolds as it Unveils Plans for Next Drug-and-Device Combo	Bruce V. Bigelow	07/19/11	San Diego
Alkermes Wins Over Investors With Plan To Become Trans-Atlantic “Big Biotech”	Luke Timmerman	07/06/11	Boston
Alkermes Acquires Elan Drug Manufacturing Unit for $960M	Luke Timmerman	05/09/11	Boston
Vertex Drug Gets Speedy FDA Review, BSX Buys Atritech, Ironwood Strikes Another Deal, & More Boston-Area Life Sciences News	Erin Kutz	01/21/11	Boston
Ex-Pfizer Exec Ed Harrigan Takes Top Job at Secretive Karuna Pharmaceuticals	Ryan McBride	01/20/11	Boston
Allon Starts Trial for Brain Disease	Luke Timmerman	01/06/11	Seattle
Biogen Announces Restructuring, FDA Approves Sunovion Drug, Acceleron Cuts Workforce, & More Boston-Area Life Sciences News	Erin Kutz	11/05/10	Boston
Allon Therapeutics Adds $10M	Luke Timmerman	11/01/10	Seattle
FDA Approves Sunovion Schizophrenia Drug	Erin Kutz	10/29/10	Boston
Alkermes Drug Approved for Opioid Addiction, Genzyme Faces Shareholder Lawsuits, NinePoint Gets $33M, & More Boston-Area Life Sciences News	Erin Kutz	10/15/10	Boston
A Nobel Laureate’s Stealthy Biotech, Its Japanese Pharma Backer, and the Englishman In Charge	Ryan McBride	10/14/10	Boston
BrainCells Inc. Buys Neuro Drug	Luke Timmerman	08/04/10	San Diego
Alkermes Reveals Higher-Than-Expected Royalty on Diabetes Drug	Luke Timmerman	04/26/10	Boston
Allon Treads Into the Great Unknown, Alzheimer’s Disease, With New Kind of Drug	Luke Timmerman	04/06/10	Seattle
San Diego’s Acadia Pharmaceuticals Updates Plans for Experimental Parkinson’s Drug	Denise Gellene	03/10/10	San Diego
AFraxis CEO Outlines Biotech’s Success With Ultra-Lean Pre-Clinical R&D in Russia	Bruce V. Bigelow	02/26/10	San Diego
NIH Chief Stresses Economic Impact of Federal Biomedical Funding	Bruce V. Bigelow	02/22/10	San Diego
Alkermes Unveils Cheaper, Easier Technique for Making Drugs Last Longer in Blood	Luke Timmerman	02/04/10	Boston
Alkermes Bets $10M on Long-Lasting Drug Technology from Startup Neighbor, Acceleron	Luke Timmerman	12/03/09	Boston
Omeros, First U.S. Biotech IPO Since February 2008, Sees Shares Drop 13 Percent in First Day	Luke Timmerman	10/08/09	Seattle
Omeros Plans to Test Waters with First Washington IPO in Two Years, Sources Say	Luke Timmerman	08/26/09	Seattle
FDA OKs Risperdal Consta for Bipolar	Luke Timmerman	05/18/09	Boston
Alkermes Knocks on Door of Biotech Big Leagues, Aims to Make Drugs of its Own	Luke Timmerman	02/12/09	Boston
TheraGenetics Bought by Avacta	Luke Timmerman	01/29/09	Boston
Omeros Grabs $3.1M	Luke Timmerman	01/28/09	Seattle
Page 1 of 2	next page »